JUNE 7-11, 1997
Cancer of the Central Nervous System
Conference with Neurosurgery Joint Section on Tumors
Chairpersons: Peter McL. Black, Boston, MA; Webster K. Cavenee, La Jolla, CA
Loew's Coronado Bay Resort, San Diego, CA

SEPTEMBER 9-13, 1997
Molecular Genetics of Cancer
Conference with the European Association for Cancer Research
Chairpersons: Eric J. Stanbridge, Irvine, CA; Walter Bodmer, Oxford, England
Hertford College, Oxford, England

SEPTEMBER 26-30, 1997
Tumor Suppressor Genes
Co-Sponsored by the National Cancer Institute of Canada
Chairpersons: Stephen H. Friend, Seattle, WA; Philip Branton, Montreal, Quebec, Canada
Victoria Conference Centre, Victoria, BC, Canada

OCTOBER 17-21, 1997
Transcriptional Control of Proliferation, Differentiation, and Development
Chairpersons: Robert Eisenman, Seattle, WA; Elaine V. Fuchs, Chicago, IL
The Sagamore Resort, Bolton Landing (Lake George), NY

DECEMBER 12-16, 1997
DNA Methylation, Imprinting, and the Epigenetics of Cancer
Chairpersons: Peter A. Jones, Los Angeles, CA; Stephen B. Baylin, Baltimore, MD; Timothy Bestor, New York, NY
El Conquistador Resort and Country Club, Las Croabas, PR

JANUARY 9-13, 1998
Programmed Cell Death
Chairpersons: John C. Reed, La Jolla, CA; Vishva M. Dixit, Ann Arbor, MI
Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

JANUARY 24-28, 1998
Angiogenesis and Cancer
Chairpersons: Judah Folkman, Boston, MA; Michael Klagsbrun, Boston, MA
Hyatt Orlando, Orlando, FL

FEBRUARY 16-21, 1998
Innovative Molecular Biology Approaches to the Prevention, Diagnosis, and Therapy of Cancer
Joint Meeting with the Japanese Cancer Association
Chairpersons: Edward Bresnick, Worcester, MA; Kaoru Abe, Tokyo, Japan
Maui Marriott Resort, Maui, HI

MARCH 28-APRIL 1, 1998
89th Annual Meeting
Chairperson: Frank J. Rauscher III, Philadelphia, PA
Morial Convention Center, New Orleans, LA

AACR members will receive brochures on the above conferences as soon as they are available. Nonmembers should call or write:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aacr.org

For regular updates to this list visit the AACR's Website, http://www.aacr.org
Custom-Tritiated Compounds for in vitro and in vivo cancer research

- Custom tritiation for functional and metabolic studies
- Effective technology for tritiation of virtually any compound, natural or synthetic
- Random and site-specific radiolabeling
- High specific activity up to 30 Ci/mmol
- New compounds are tritiated in 2 weeks
- Affordable pricing, no feasibility charges

Experience with therapeutic, tobacco and food metabolites, phytochemicals, hormones, lipids, nucleoside analogs, oligonucleotides, peptides, etc.

Ready for delivery:
- $^3$Hgenistein
- $^3$Hquercetin
- $^3$Hcatechin
- $^3$Hresveratrol

SibTech, Inc.
Tel. (201) 871-7428  FAX (201) 568-7308
E-mail: sibtech@world.std.com

---

Annals of the New York Academy of Sciences

The Camptothecins
From Discovery to the Patient

Panayotis Pantazis (Stehlin Foundation for Cancer Research), Beppino C. Giovanella (Stehlin Foundation for Cancer Research) & Mace Rothenberg (The University of Texas Health Science Center), Editors

Camptothecin and its derivatives are rapidly establishing themselves as promising anticancer agents. The proceedings of the first major conference on camptothecins, this volume integrates aspects of their chemistry, mechanism, pharmacology and clinical results. It indicates the importance of camptothecins as chemotherapeutic agents and emphasizes the importance of the xenograft model.

339 pp.; 29 papers; 8 poster papers
$100.00

Communication with the Cancer Patient

Information and Truth

Antonella Surbone (Memorial Sloan-Kettering Cancer Center) & Matjaz Zwitter (Institute of Oncology, Ljubljana, Slovenia), Editors
Invited papers from approximately 30 countries following the workshop “Communication and Ethics” of the Organization of European Institute Conference on Cancer and Quality of Life, May 12–14, 1995

In many parts of the world seriously ill patients are not informed of their diagnoses. Consequences of this for the patient are not being informed about the therapy and its possible side effects and ultimately deprivation of autonomy. Telling the truth to a patient is not simply a matter of providing information. Rather, it is a matter of two-way communication, the result of a relationship between doctor and patient that develops over time in the context of a given culture. This volume oncologists practicing in countries throughout the world give their perceptions of how truth-telling is handled in their cultures.

538 pp.; 53 papers
$90.00

Interleukin-12
Cellular and Molecular Immunology of an Important Regulatory Cytokine

Michael T. Lotze (University of Pittsburgh School of Medicine), Maurice K. Gately (Hoffmann-La Roche, Inc.), Giorgio Trinchieri (The Wistar Institute) & Stanley E. Wolfe (Genetics Institute, Inc.), Editors

This examination of current work on IL-12 focuses on the emerging understanding of this exciting new growth factor, including its production, receptor interaction, signal transduction, interactions with other cytokines, its use as a therapy for AIDS and cancer, and its role in promoting an effective cellular response to microbial pathogens.

457 pp.; 32 papers; 34 poster papers
$125.00
Add $5.00 per book shipping and handling on orders totaling less than $300.00. Academy members receive substantial discounts on all publications. Inquire for information on membership.

TO ORDER, PLEASE CONTACT:

New York Academy of Sciences
Publications, 2 East 63rd Street, New York, NY 10021
F: 212.838.0230 or 900.843.6927, ext. 341
F: 212.888.2894
E: publications@nyas.org
Visit our website at http://www.nyas.org

---

ONCOLOGY RESEARCH

Assistant or Associate Professor Level

The Cancer Institute of New Jersey and the Departments of Medicine and Surgery at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School are looking for an M.D. or M.D./Ph.D. physician scientist with research interests and a record of accomplishments in laboratory or clinical research in molecular epidemiology and/or cancer chemoprevention. The successful applicant must be a board certified physician who can participate in the care of patients in a teaching hospital setting. Responsibilities will include interfacing between a strong laboratory research program in carcinogenesis and cancer prevention and the clinical services of The Cancer Institute of New Jersey. The candidate will have an academic appointment in an appropriate department, (e.g., Medicine, Surgery) with a joint appointment in a basic science department.

Applicants should submit curriculum vitae to: Joseph Aisner, M.D., Chair, Search Committee, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901.

UMDNJ is an Affirmative Action/Equal Opportunity Employer, m/f/d/v, and a member of the University Health System of New Jersey. Minorities and women are encouraged to apply.
SECOND INTERNATIONAL MOUSE LUNG TUMORIGENESIS SYMPOSIUM

The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Research Institute
Columbus, Ohio
June 18–20, 1997

Scientific Organizers:

Gary Stoner, Ph.D.
Director of Basic Research
OSU Comprehensive Cancer Center
Columbus, Ohio
and
Alvin Malkinson, Ph.D.
Professor, Department of Pharmacology
University of Colorado School of Pharmacy
Denver, Colorado

This meeting will summarize current information in the field of mouse lung tumorigenesis and its relationship to human lung cancer. Topics and invited speakers include: Etiology (Nesnow, Stoner, Witschi), Genetics (Anderson, Dragani, Gould), Molecular Alterations (Belinsky, Forkert, Malkinson, Ruch, Sabourin, You), Chemoprevention (Castonguay, Lubert, Moody, Stoner, Wattenberg, Yang). A poster session will be included.

Please write for information about registration, abstract preparation and lodging to John L. Wilson, Ph.D., OSU Comprehensive Cancer Center, 941 Chatham Lane, Suite 315, Columbus, Ohio 43221

HUMAN BREAST CANCER TISSUES FOR RESEARCH

The NCI Cooperative Breast Cancer Tissue Resource can provide researchers with access to more than 6,000 cases of formalin-fixed, paraffin-embedded primary breast cancer tissues, with associated pathology and clinical data. Tissue and data are available from patients treated in four diverse geographic areas of the United States. Tissue sections are prepared to meet the criteria of individual research protocols. All specimens are reviewed to verify the pathologic diagnosis. Clinical and outcome data includes: diagnosis, demographic data, extent of disease, treatment, followup, recurrence, survival, and vital status. The Resource cannot provide patient identification or family information.

To request specimens and data, send a short letter outlining the aims of the proposed research to the address shown below. Briefly describe the technical approach and proposed technique(s) that can be applied to paraffin-embedded specimens. Include an estimate of the number of cases needed for the study. The request will be reviewed upon receipt and a more detailed proposal will be requested if the study appears reasonable and the Resource has the requested materials. There are no specific receipt dates and every attempt will be made to evaluate requests expeditiously.

Additional information may be obtained on the Resource web site, which contains a searchable database of cases, at: http://wwwic.cci.nih.gov/index/html or from: Sherrill Long, Information Management Services, Inc.
12501 Prosperity Drive, Suite 200 Silver Spring, MD 20904
Telephone (301) 680-9770

GENERAL MOTORS CANCER RESEARCH FOUNDATION ANNUAL CONFERENCE

Cutaneous Malignancies

June 10 and 11, 1997
Jack Masur Auditorium
Clinical Center
National Institutes of Health
Bethesda, Maryland

Some of the world's foremost researchers will present their latest findings in skin cancer prevention, causes, and treatment at this year's General Motors Cancer Research Foundation Annual Scientific Conference. In addition, lectures by the winners of the 1997 General Motors Cancer Research Foundation Awards will be featured.

To register, call (302) 838-8745, fax (302) 838-8755, e-mail cpannee@erols.com or write: General Motors Cancer Research Foundation, c/o Campbell, Peachey & Associates, 111 Quincy Place, N.E., Washington, D.C. 20002.
Hit our Home Page on the World Wide Web!

http://www.aacr.org

Our web site features:

AACR scientific meeting schedule

Table of Contents of AACR journals

Instructions for Authors

Information about AACR Research Fellowships and Travel Awards

Plus . . . The latest AACR newsletter, and much more!
MOLECULAR GENETICS OF CANCER

Joint Conference of the
American Association for Cancer Research
and the
European Association for Cancer Research

September 9-12, 1997
Hertford College, University of Oxford
Oxford, England

CONFERENCE CHAIRPERSONS
Eric J. Stanbridge / Irvine, CA
Sir Walter Bodmer / Oxford, England

SCIENTIFIC PROGRAM

Keynote Lecture
Richard D. Klausner / Bethesda, MD

Lower Eukaryotes - What they Tell Us About Cancer Genes
Roel Nusse / Stanford, CA
Tian Xu / New Haven, CT
Ronald H. A. Plasterk / Amsterdam, The Netherlands
Joan Massague / New York, NY

New Approaches to Cloning Tumor Suppressor Genes
Adi Kimchi / Rehovot, Israel
Stanley N. Cohen / Stanford, CA
Additional speakers to be announced

Cell Cycle Genes and Cancer
Paul Nurse / London, England
Gordon Peters / London, England
Charles J. Sherr / Memphis, TN
Xin Lu / London, England

Molecular Analysis of Multistep Progression
Peter Collins / Goteborg, Sweden
Paul Cairns / Baltimore, MD
Helene S. Smith / San Francisco, CA

Transgenic Mouse Models of Cancer
Walter Bodmer / Oxford, England
Terry A. Van Dyke / Chapel Hill, NC
Allan Bradley / Houston, TX
Anton J. M. Berns / Amsterdam, The Netherlands

Molecular Genetics of Cancer of the Cervix
Eric J. Stanbridge / Irvine, CA
Karen H. Vousden / London, England
Garret M. Hampton / La Jolla, CA

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: June 2, 1997

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483 USA
215-440-9300 215-440-9313 (FAX)
e-mail: aacr@aacr.org
AACR Website: http://www.aacr.org

European Association for Cancer Research
Cancer Research Laboratory
University of Nottingham
Nottingham NG7 2RD UK
+44-115-951-5114 +44-115-951-5115 (FAX)
e-mail: paul.saunders@nottingham.ac.uk
In Situ PCR

We have answers:

If you want to know what in situ PCR can bring to your research, here's an excellent opportunity to get your questions answered.

By combining in situ hybridization and PCR, researchers now have the specificity and sensitivity they need to localize low-copy target sequences within individual cells and correlate the results with cell morphology. In situ PCR can be used for the following applications:

- Analyze cell-specific gene expression
- Identify cells with low-copy infectious agents
- Pinpoint rare gene alterations
- Locate cells with gene rearrangements

In An Approach to In Situ PCR, by Fraser Lewis, you'll find practical information about implementing in situ PCR in your laboratory, including basic guidelines, experimental variables, and an up-to-date bibliography. And a copy is yours free from PE Applied Biosystems.

There's no question about it. For answers about in situ PCR, this is one offer you don't want to pass up. To request your FREE edition of An Approach to In Situ PCR, fill out the attached reply card, or visit our web site at www2.perkin-eler.com/insitu today.

An Approach to
In Situ PCR

PE Applied Biosystems

Europe Langen, Germany Tel: 49 (0)6103 798 307 Fax: 49 (0)6103 798 319 Japan Tokyo, Japan Tel: (0473) 80-8500 Fax: (0473) 80-8525 Latin America Mexico City, Mexico Tel: 52-5-651-7077 Fax: 52-5-651-6223 Australia Melbourne, Australia Tel: (03) 9212-6545 Fax: (03) 9212-6540

Perkin-Elmer PCR reagents are developed and manufactured by Roche Molecular Systems, Inc., Branchburg, New Jersey, U.S.A. 

The PCR process is covered by patents owned by Hoffman-La Roche Inc. and Hoffmann-La Roche Ltd. 

Roche Diagnostics is a registered trademark of Hoffmann-La Roche Inc. and Hoffmann-La Roche Ltd. 

The Roche logo is a registered trademark of Hoffman-La Roche Inc. All products except those noted otherwise are developed and produced under the quality requirements of ISO 9000.
Our current cover features Oscar Auerbach, an early pioneer in the area of the pathogenesis of lung cancer in relation to tobacco use, who passed away in January 1997 at the age of 92. His studies played an important part in the 1964 Report of the Surgeon General’s Committee on Smoking and Health, and he was commended by the Surgeon General for his significant contributions to Health Consequences of Smoking—A Public Health Service Review—1967. It was Dr. Auerbach’s application of novel experimental and autopsy methods some 40 years ago, when epidemiological data were not as firmly established as they are today, that decisively bolstered the evidence on the role of cigarette smoking in human carcinogenesis. Reasoning that lung cancer in smokers should be preceded by precancerous cellular changes in the tracheo-bronchial sections of smokers, Dr. Auerbach initiated a series of experimental studies that supplemented and extended the then growing body of epidemiologic data in this area by revealing that autopsies of smokers who died of causes other than lung cancer had early precancerous changes: hyperplasia, metaplasia, and carcinoma in situ (New Engl. J. Med., 256: 97–104, 1957). Given wide public exposure, these data made it clear to the general public as well as to a skeptical segment of the medical population that tobacco smoke indeed had toxic properties that, over extended periods of exposure, caused a series of pathological changes inevitably leading to cancer. Briefly summarized, he found that the number and extent of precancerous lesions were greater in heavier than in lighter smokers (New Engl. J. Med., 265: 253–267, 1961) and that more of these changes were found in the tracheo-bronchial areas of smokers who died of lung cancer than of those who died of other causes or those who were not smokers. He also extended these studies to include data on women as well as men, cigar and pipe smokers, older versus younger smokers, and nonsmokers living in urban rather than rural areas (New Engl. J. Med., 267: 111–118, 1962). An important finding was that ex-cigarette smokers had fewer epithelial changes than matched cigarette smokers, with evidence of disintegrating nuclei in ex-smokers, an indication of a healing process after cessation of smoking (New Engl. J. Med., 267: 119–125, 1962). His further work led to knowledge of the role of cigarettes in the development of emphysema and the thickening of the walls of coronary and other arteries and arterioles (Postgrad. Med., 40: 95–100, 1966).

Dr. Auerbach lectured widely on cigarette smoking and cancer at professional meetings, and the American Cancer Society built a campaign around the hopeful results of his studies on ex-smokers. He authored over 130 articles, and thousands of reprints of his papers have been distributed to scientists and to medical and graduate school students.

Dr. Auerbach received his M.D. from New York Medical College in 1929. After advanced training in pathology at the University of Vienna where he was a Research Fellow, Dr. Auerbach returned to the U.S. and joined the Sea View Hospital on Staten Island, where he worked on tuberculosis. Then, after serving 2 years in the U.S. Navy, he moved on to the VA Hospital on Staten Island, where he became Chief, Laboratory Services. In 1952, he went to the VA Hospital in East Orange, NJ, where he held the post of Chief, Laboratory Services through 1959 before assuming the position of Senior Medical Investigator in 1960. From 1949–61, he was also on the faculty of the New York Medical College and served as Professor of Pathology from 1962–71. From 1966 to the time of his death, he served as Professor of Pathology at the College of Medicine and Dentistry of New Jersey. He has been honored widely by the National Civil Service League, the Administrator for Veterans Affairs, the American College of Chest Physicians, the Alton Ochsner Foundation, and the Academy of Medicine of New Jersey, and he was named an Outstanding Alumnus of the New York Medical College.

For the information on Dr. Auerbach’s career, we are greatly indebted to Lawrence Garfinkel, who together with the late E. C. Hammond participated in much of Dr. Auerbach’s American Cancer Society-supported research.

Sidney Weinhouse